Key facts
- BioOrbit’s last known valuation is $26.2M (Feb 2026).
- It has raised $14.3M; the latest was Seed Round ($14.3M) in Feb 2026.
- Notable investors include European Innovation Council, Tech Nation Group, Seedcamp, Seraphim Space, 7percent Ventures — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for BioOrbit
- ·The full record, as it builds
Funding rounds
No funding rounds for BioOrbit are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BioOrbit
Operator of a pharmaceutical factory intended for large-scale crystallization of protein drugs in microgravity. The company utilizes microgravity to overcome the challenges of protein crystallization on Earth, resulting in more perfect crystals with a smaller size distribution, ideal for pharmaceutical use, enabling hospital-based intravenous administration to convenient at-home subcutaneous injection, and addressing the growing demand for home-based care.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2023
- Employees
- 7
- Website
- bioorbit.space/
- Ownership
- Privately Held (backing)
BioOrbit doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BioOrbit shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BioOrbit in its N-PORT filings yet. We sweep new filings monthly.